You are here: Home ยป Archives for healthcare

شركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية

الاتفاقية تفتح المجال أمام علاجات Profound التي لا تستلزم أي جراحة أو إشعاع لاستئصال الأنسجة المريضة، لتخترق بذلك أكبر سوق للرعاية الصحية في الشرق الأوسط

تم الحصول بالفعل على جميع الموافقات التنظيمية اللازمة لاستيراد وبيع تقنيتي الاستئصال المتقدمتين من شركة Profound في المملكة العربية السعودية

تورنتو والرياض، المملكة العربية السعودية, Nov. 13, 2025 (GLOBE NEWSWIRE) —

يسر شركة Profound Medical (NASDAQ:PROF; TSX:PRN) (“Profound” أو “الشركة”)، وهي شركة أجهزة طبية في مرحلة تجارية تُطوّر وتُسوّق علاجات بدون جراحات تعمل بالذكاء الاصطناعي (“AI”)، وموجهة بالرنين المغناطيسي، لاستئصال الأنسجة المريضة، أن تُعلن أنها أبرمت اتفاقية توزيع وتوريد حصرية لتقنيتي TULSA–PRO® و Sonalleve®في المملكة العربية السعودية مع شركة Al Faisaliah Medical Systems (“FMS”)، وهي شركة تابعة لإحدى أبرز تكتلات الأعمال في المملكة، مجموعة Al Faisaliah Group (“AFG”).

وتعد Profound الشركة الوحيدة التي تجمع بين قدرات التصوير في الوقت الحقيقي والتصوير الحراري للرنين المغناطيسي (“MR”) مع تصميمات العلاج التي تعتمد على الذكاء الاصطناعي للسماح للأطباء بمعالجة الأنسجة المريضة بدقة ولطف دون أي جراحة أو غلي أو كي الأنسجة المرتبطة أو فقدان الدم أو الألم الشديد/ المُطوَّل أو الحاجة إلى الإقامة في المستشفى لليلة واحدة.

يظل التسويق التجاري لدواء TULSA–PRO، المُصمم خصيصًا لعلاج أمراض البروستاتا (سرطان البروستاتا وتضخم البروستاتا الحميد “BPH” أو أيٍ منهما) في الولايات المتحدة هو الأولوية القصوى لفريق المبيعات المباشرة للشركة. يمثل TULSA Procedure™، الذي يتم إجراؤه باستخدام نظام TULSA–PRO من Profound، تقدمًا كبيرًا في علاج البروستاتا. بدلاً من الجراحة أو الإشعاع، يتم تطبيق إجراء TULSA داخل جناح التصوير بالرنين المغناطيسي لتسخين أنسجة البروستاتا بدقة ولطف “وصولًا لدرجة الحرارة اللازمة للقضاء على الأنسجة المريضة” (55–57 درجة مئوية) باستخدام الموجات فوق الصوتية الاتجاهية، مع حماية الأعصاب المحيطة والبنية التشريحية. من حيث نية العلاج، في حين أن TULSA–PRO يتمتع بالمرونة التي تمكننا من استخدامه في جميع عمليات الاستئصال، بما في ذلك الاستئصال البؤري واستئصال نصف الغدة، فإن غالبية إجراءات TULSA هي إما استئصال الغدة بالكامل أو استئصال الغدة بالكامل تقريبًا. في أواخر عام 2024، أصدرت مراكز الرعاية الطبية والخدمات الطبية (CMS) في الولايات المتحدة القاعدة النهائية لنظام الدفع المستقبلي للمرضى الخارجيين (OPPS) (“القاعدة النهائية”) لرموز الفئة 1 الجديدة CPT® وأوصافها التي تغطي إجراء TULSA، والتي دخلت حيز التنفيذ في 1 يناير 2025. بموجب القاعدة النهائية، تم وضع سداد تكاليف TULSA في تصنيف الدفع الخارجي لمستوى 7 في طب المسالك البولية (APC). حتى الآن، خضع أكثر من 4000 رجل لإجراء TULSA، واعتبارًا من آخر تقرير (أكتوبر 2025)، بلغ عدد أنظمة TULSA–PRO المثبتة لدى Profound 67 نظامًا.

ويحظى المنتج الثاني لشركة Profound، وهو Sonalleve، والذي يُقدّم يتم في المقام الأول كعملية بيع رأسمالية لمرة واحدة، باهتمام تجاري متزايد، وخاصة خارج الولايات المتحدة. يستخدم Sonalleve نفس تقنية التصوير بالرنين المغناطيسي والتصوير الحراري مثل TULSA–PRO، ويجمع ذلك مع الموجات فوق الصوتية المركزة من خارج الجسم لعلاج الأمراض. توجد حاليًا عشرة أجهزة Sonalleve عاملة في أجزاء من أوروبا والصين وجنوب شرق آسيا – حيث تم بالفعل علاج أكثر من 4000 امرأة باستخدام هذه التكنولوجيا لعلاج الانتباذ البطاني الرحمي والأورام الليفية الرحمية، وهي أمراض تصيب الرحم ويمكن أن تسبب آلامًا مزمنة وحيضًا ثقيلًا وطويلًا أو أيًا منهما. وقد أثبت العلاج باستخدام Sonalleve تخفيف الألم والأعراض دون التأثير على احتياطي المبيض، كما تشير تقارير إلى محافظة النساء على خصوبتهن بعد العلاج. ويُستخدم Sonalleve الآن أيضًا في الأبحاث والتجارب السريرية في أوروبا لاستئصال أنسجة سرطان البنكرياس وأمراض الأورام الأخرى. على مدى السنوات الخمس الماضية، قدمت منظمات الأبحاث في أوروبا وكندا ما يقرب من 10 مليون دولار أمريكي لإجراء المزيد من الأبحاث السريرية باستخدام Sonalleve لعلاج أمراض متعددة تهدد الحياة في كثيرٍ من الأحيان.

مع استمرار تزايد اهتمام المستخدمين بتقنيات Profound، تنشر الشركة فريق المبيعات المباشرة الخاص بها في أمريكا الشمالية، في حين تتعاون مع شركاء توزيع استراتيجيين مختارين لدعم إمكانات الأعمال وقاعدة العملاء في أجزاء أخرى من العالم.

وصرح Arun Menawat، الرئيس التنفيذي ورئيس مجلس إدارة شركة Profound، قائلاً: “يشرفنا أن نتعاون مع شركة FMS، إحدى شركات توزيع الأجهزة الطبية الرائدة في المملكة العربية السعودية، لتوزيع كل من TULSA–PRO وSonalleve”. “إن التسويق والتوزيع الناجحين لعلاجاتنا الخالية التي لا تستلزم جراحة لاستئصال الأنسجة المريضة يتطلب فهمًا عميقًا لديناميكيات السوق الإقليمية والاحتياجات المحددة للأطباء والمرضى المحليين. وبفضل سجلها الحافل في تقديم إجراءات الأورام المتقدمة وغيرها من التقنيات الطبية في المملكة، فإننا على ثقة بأن شركة FMS هي الشريك المثالي لنا”.

قال المدير العام لشركة FMS، السيد Abdullah Al Melik: “مع توجه المملكة العربية السعودية نحو التنوع الاقتصادي في إطار رؤية 2030، تلتزم كل من FMS وشركتنا الأم، AFG، بالقيام بدور حاسم في تشكيل مستقبل البلاد. وتعد المجموعة من أهم مُقدمي المعدات والخدمات للمستشفيات القائمة، كما تمتلك وتدير مرافقها الطبية المتخصصة بفعاليةٍ. بفضل شراكتنا مع شركة Profound، نحن متحمسون للغاية لتقديم تقنياتها الفريدة التي لا تستلزم الجراحة أو الإشعاع إلى المستشفيات ومراكز العلاج السعودية التي تهدف إلى أن تكون رائدة عالميًا في نتائج المرضى. نتطلع إلى العمل بشكل وثيق مع فريق Profound.”

نبذة عن شركة Al Faisaliah Medical Systems

تأسست شركة FMS في عام 1973، وكانت في البداية قسم الرعاية الصحية التابع لشركة AFG، حتى تأسيسها كشركة مستقلة في عام 1993. بفضل سابقة أعمالها الضخمة التي تضم العديد من الشركاء والمنتجات، تتمكن الشركة من تقديم حلول متكاملة ومعقدة لمعدات الرعاية الصحية من مصدر واحد لأكبر مقدمي الرعاية الصحية في المنطقة. تعد شركة FMS مزودًا رئيسيًا لحلول الرعاية الصحية المتنوعة، وذلك من خلال انتشار عملياتها في جميع أنحاء المملكة العربية السعودية، حيث توفر أحدث المعدات والحلول لمختلف الاستخدامات مثل الأورام والعمليات والملاحظة والرعاية الحرجة وأمراض القلب والأوعية الدموية وغيرها. لمزيد من المعلومات، يُرجى زيارة www.tibbiyah.com/fms.

نبذة عن Al Faisaliah Group

AFG هي شركة قابضة مملوكة للقطاع الخاص يقع مقرها الرئيسي في الرياض، المملكة العربية السعودية، وتعمل في جميع أنحاء الشرق الأوسط. وقد اشتق اسم الشركة من اسم مؤسسها عبدالله الفيصل الابن الأكبر للملك الراحل فيصل بن عبد العزيز. تأسست المجموعة في عام 1971، وتلعب أدوارًا قياديةً في العديد من الصناعات بما في ذلك منتجات الألبان والإلكترونيات والرعاية الصحية وخدمات الطعام. وتدير AFG أيضًا ذراع رأس المال الاستثماري لشركات (Al Faisaliah Ventures) التي تستثمر في الشركات الرائدة عالميًا وإقليميًا. وتحظى المجموعة بتقدير كبير في مختلف أنحاء المنطقة بفضل قيمها الراسخة وإدارتها المحترفة وشراكاتها الاستراتيجية التي تمتد لعقود من الزمن مع شركات محلية وعالمية رائدة بما في ذلك Sony وDanone وPhilips. لمزيد من المعلومات، يُرجى زيارة www.alfaisaliah.com.

نبذة عن شركة Profound Medical

Profound هي شركة أجهزة طبية في مرحلة تجارية تُطوّر وتُسوّق علاجات بدون جراحات تعمل بالذكاء الاصطناعي (“AI”)، وموجهة بالرنين المغناطيسي، لاستئصال الأنسجة المريضة.

تعمل شركة Profound على تسويق TULSA–PRO® وهي تقنية تجمع بين التصوير بالرنين المغناطيسي في الوقت الفعلي والتخطيط المعزز بالذكاء الاصطناعي والموجات فوق الصوتية عبر مجرى البول التي يتم تشغيلها آليًا والتحكم في درجة الحرارة ذات الحلقة المغلقة. إن إجراء TULSA Procedure™‎، الذي يتم إجراؤه باستخدام نظام TULSA–PRO، لديه القدرة على أن يصبح طريقة علاج رئيسية في جميع أنوع أمراض البروستاتا؛ بدءًا من سرطان البروستاتا منخفض أو متوسط أو عالي الخطورة؛ إلى المرضى الهجينين الذين يعانون من سرطان البروستاتا وفرط تنسج البروستاتا الحميد (“BPH”)؛ إلى الرجال المصابين بتضخم البروستاتا الحميد فقط؛ وأيضًا، إلى المرضى الذين يحتاجون إلى علاج إنقاذي لسرطان البروستاتا الموضعي المتكرر بالإشعاع. يستخدم إجراء TULSA توجيهات التصوير بالرنين المغناطيسي في الوقت الفعلي لضمان الدقة في الحفاظ على القدرة على التحكم في البول والوظيفة الجنسية لدى المرضى، مع قتل أنسجة البروستاتا المستهدفة من خلال تقنية امتصاص الصوت الدقيقة التي تسخنها بلطف حتى تصل إلى 55–57 درجة مئوية. إجراء TULSA هو إجراء جراحي لا يستلزم جراحة أو إشعاع ويتم إجراؤه في جلسة واحدة تستغرق بضع ساعات. يمكن علاج جميع أشكال وأحجام البروستاتا تقريبًا بأمان وفعالية وكفاءة باستخدام إجراء TULSA. لا ينطوي الإجراء على نزيف؛ ولا يتطلب الأمر البقاء في المستشفى؛ ويبلغ معظم مرضى TULSA عن تعافيهم السريع وعودتهم إلى روتينهم الطبيعي. تم وضع علامة CE على منتج TULSA–PRO، وتمت الموافقة عليه من قبل وزارة الصحة الكندية، وتمت الموافقة عليه بموجب 510(k) من قبل Food and Drug Administration (“FDA”).

تقوم شركة  Profoundبتسويق Sonalleve®، وهي منصة علاجية مبتكرة حاصلة على علامة CE لعلاج الأورام الليفية الرحمية، والانتباذ العضلي الليفي، وتخفيف آلام نقائل العظام، والأورام الليفية العضلية، وأورام العظام العظمية. كما تمت الموافقة على Sonalleve من قبل إدارة المنتجات الطبية الوطنية الصينية لعلاج الأورام الليفية الرحمية غير الجراحية، وحصل على موافقة FDA بموجب الإعفاء الإنساني للجهاز لعلاج ورم العظم العظمي. وتجري شركة Profound حالياً المراحل الأولى من استكشاف أسواق علاجية محتملة إضافية لجهاز Sonalleve حيث ثبت أن هذه التقنية لها تطبيقات سريرية، مثل الاستئصال غير الجراحي لسرطانات البطن والحرارة العالية لعلاج السرطان.

البيانات التطلعية

يتضمن هذا البيان الصحفي بيانات تطلعية بشأن شركة Profound وأعمالها والتي قد تشمل، على سبيل المثال لا الحصر، التوقعات المتعلقة بفعالية تقنية Profound في علاج سرطان البروستاتا، وتضخم البروستاتا الحميد، والأورام الليفية الرحمية، وعلاج الألم التلطيفي، وورم العظام العظمي؛ ومدى وتوقيت استكمال Profound لمبيعات نظام TULSA–PRO®‎ من قنوات المبيعات المؤهلة؛ وتوقعات Profound للإيرادات المستقبلية؛ ونجاح إستراتيجية Profound التجارية وأنشطتها فيما يتعلق بـ TULSA–PRO. في كثير من الأحيان، ولكن ليس دائمًا، يمكن التعرف على البيانات التطلعية من خلال استخدام كلمات مثل “يخطط”، “من المتوقع”، “يتوقع”، “مجدول”، “ينوي”، “يتأمل”، “يتوقع”، “يعتقد”، “يقترح” أو الاختلافات (بما في ذلك الاختلافات السلبية) لهذه الكلمات والعبارات، أو تنص على أن بعض الإجراءات أو الأحداث أو النتائج “قد” أو “يمكن” أو “سوف” يتم اتخاذها أو حدوثها أو تحقيقها. وتستند مثل هذه البيانات إلى التوقعات الحالية لإدارة شركة Profound. قد لا تقع الأحداث والظروف التطلعية التي تمت مناقشتها في هذا البيان الصحفي بحلول تواريخ محددة أو قد لا تقع على الإطلاق وقد تختلف ماديًا نتيجة لعوامل الخطر المعروفة وغير المعروفة وعدم اليقين الذي يؤثر على الشركة، بما في ذلك المخاطر المتعلقة بصناعة الأجهزة الطبية، والموافقات التنظيمية، والسداد، والعوامل الاقتصادية، وأسواق الأسهم بوجهٍ عامٍ والمخاطر المرتبطة بالنمو والمنافسة. على الرغم من أن Profound حاولت تحديد العوامل المهمة التي قد تتسبب في اختلاف الإجراءات أو الأحداث أو النتائج الفعلية بشكل مادي عن تلك الموصوفة في البيانات التطلعية، إلا أنه قد تكون هناك عوامل أخرى تتسبب في اختلاف الإجراءات أو الأحداث أو النتائج عن تلك المتوقعة أو المقدرة أو المقصودة. لا يمكن ضمان أي بيان تطلعي. تم وصف العوامل والمخاطر الأخرى التي قد تؤدي إلى اختلاف النتائج الفعلية بشكل مادي عن تلك المنصوص عليها في البيانات التطلعية في التقرير السنوي لشركة Profound على النموذج 10–K والملفات الأخرى المقدمة إلى هيئات تنظيم الأوراق المالية الأمريكية والكندية، والمتاحة على www.sedarplus.ca وwww.sec.gov. باستثناء ما تقتضيه قوانين الأوراق المالية المعمول بها، فإن البيانات التطلعية تتحدث فقط اعتبارًا من تاريخ إصدارها، ولا تتعهد Profound بأي التزام بتحديث أو مراجعة أي بيان تطلعي علنًا، سواء نتيجة لمعلومات جديدة أو أحداث مستقبلية أو غير ذلك، بخلاف ما يقتضيه القانون.

لمزيد من المعلومات، يرجى التواصل مع:

Stephen Kilmer
علاقات المستثمرين
[email protected]
هاتف: 647.872.4849


GLOBENEWSWIRE (Distribution ID 9575020)

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Agreement creates runway for Profound’s incision–free and radiation–free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East

All required regulatory approvals to import and sell Profound’s two advanced ablative technologies in Saudi Arabia are already in place

TORONTO and RIYADH, Saudi Arabia, Nov. 11, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial–stage medical device company that develops and markets artificial intelligence (“AI”)–powered, MRI–guided, incision–free therapies for the ablation of diseased tissue, is pleased to announce that it has entered into an exclusive distribution and supply agreement for its TULSA–PRO® and Sonalleve® technologies in Saudi Arabia with Al Faisaliah Medical Systems Co. (“FMS”), a subsidiary of one of the Kingdom’s most prominent business conglomerates, Al Faisaliah Group (“AFG”).

Profound is the only company that combines the real–time imaging and thermography capabilities of magnetic resonance (“MR”) with AI–driven treatment designs to allow physicians to precisely and gently address diseased tissue without any incision, associated tissue boiling or charring, blood loss, severe/prolonged pain, or need for overnight hospital stay.

U.S. commercialization of TULSA–PRO, designed specifically for the treatment of prostate disease (prostate cancer and/or benign prostatic hyperplasia, “BPH”), remains the top priority for the Company’s direct sales team. The TULSA Procedure™, performed using Profound’s TULSA–PRO system, is a significant advancement in prostate care. Instead of surgery or radiation, the TULSA procedure is performed inside an MRI suite to precisely and gently heat prostate tissue to ‘kill temperature’ (55–57°C) with directional ultrasound, while protecting surrounding nerves and anatomy. By intention–to–treat, while TULSA–PRO has the flexibility to be used for all ablations, including focal and hemi–gland, the majority of TULSA Procedures are either whole–gland or near–whole–gland ablations. In late 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued its outpatient prospective payment system (OPPS) final rule (“Final Rule”) for the three new CPT® Category 1 codes and their descriptors covering the TULSA procedure, which became effective on January 1, 2025. With the Final Rule, TULSA reimbursement was established at Urology Level 7 Ambulatory Payment Classification (APC). To–date, more than 4,000 men have undergone the TULSA Procedure, and as of last report (October 2025), Profound’s TULSA–PRO installed base stood at 67 systems.

Profound’s second product, Sonalleve, which is offered primarily as a one–time capital sale, is also gaining increasing commercial interest, particularly outside of the United States. Sonalleve uses the same MR imaging and thermographic technology as TULSA–PRO, and combines that with focused ultrasound from outside the body to treat disease. There are currently ten Sonalleve devices operational in parts of Europe, China and Southeast Asia – where over 4,000 women have already been treated with the technology for adenomyosis and uterine fibroids, diseases of the uterus that can cause chronic pain and heavy and/or prolonged menstruations. Treatment with Sonalleve has demonstrated pain and symptom relief without affecting the ovarian reserve, and with reports of women preserving their fertility. Sonalleve is also now being used in research and clinical trials in Europe for the ablation of pancreatic cancer tissue and other oncological disease. Over the last five years, approximately $10 million has been granted by research organizations in Europe and Canada to further conduct clinical research using Sonalleve for multiple, often life–threatening, diseases.

As user interest in Profound’s technologies continues to build, the Company is deploying its own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world.

“We’re honored to partner for the distribution of both TULSA–PRO and Sonalleve with FMS, one of the leading medical device distributors in the Kingdom of Saudi Arabia,” commented Profound’s CEO and Chairman, Arun Menawat. “Successfully marketing and distributing our incision–free therapies for the ablation of diseased tissue requires a deep understanding of regional market dynamics and the specific needs of local clinicians and patients. With its proven track record in introducing advanced oncological procedures and other medical technologies in the Kingdom, we’re confident that FMS is the ideal partner for us.”

FMS’ GM, Mr. Abdullah Al Melik, said, “As Saudi Arabia moves toward economic diversification under Vision 2030, both FMS and our parent company, AFG, are committed to playing a crucial role in shaping the country’s future. The group is a major provider of equipment and services to existing hospitals, and also actively owns and operates its own specialized medical facilities. With our partnership with Profound, we're extremely excited to bring its unique, incision– and radiation–free ablative technologies to Saudi hospitals and treatment centers that aim to be worldwide leaders in patient outcomes. We look forward to working closely with the Profound team.”

About with Al Faisaliah Medical Systems Co.

Founded in 1973, FMS was initially the healthcare division of AFG, until its establishment as an independent company in 1993. Its broad portfolio of partners and products enables it to deliver complex, integrated, single–source healthcare equipment solutions to the largest healthcare providers in the region. With operations across the Kingdom of Saudi Arabia, FMS is a major provider of diversified healthcare solutions, supplying state–of–the–art equipment and solutions for various uses such as oncology, operations, monitoring and critical care, cardiovascular and others. For further information, visit www.tibbiyah.com/fms.

About Al Faisaliah Group

AFG is a privately held holding company headquartered in Riyadh, Saudi Arabia, operating across the wider Middle East. Its name is derived from the name of its founder, Abdullah Al Faisal, eldest son of the late King Faisal. Founded in 1971, the Group holds leading positions in multiple industries including Dairy, Electronics, Healthcare and Food Service. AFG also operates a corporate venture capital arm (Al Faisaliah Ventures) that invests in global and regional disruptive players. The Group is recognized across the region for its strongly–held values, professional management and decades–long strategic partnerships with leading local and global firms including notably Sony, Danone and Philips. For further information, visit www.alfaisaliah.com.

About Profound Medical Corp.

Profound is a commercial–stage medical device company that develops and markets AI–powered, MRI–guided, incision–free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA–PRO®, a technology that combines real–time MRI, AI–enhanced planning, robotically–driven transurethral ultrasound and closed–loop temperature feedback control. The TULSA Procedure™, performed using the TULSA–PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low–, intermediate–, or high–risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio–recurrent localized prostate cancer. The TULSA Procedure employs real–time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55–57°C. The TULSA Procedure is an incision– and radiation–free “one–and–done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA–PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non–invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non–invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward–Looking Statements

This release includes forward–looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; the extent and timing of Profound’s completion of TULSA–PRO® system sales from its qualified sales pipeline; Profound’s expectations for future revenues; and the success of Profound’s commercialization strategy and activities for TULSA–PRO. Often, but not always, forward–looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward–looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward–looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward–looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward–looking statements are described in Profound's Annual Report on Form 10–K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward–looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward–looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849


GLOBENEWSWIRE (Distribution ID 9573632)

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle–free injection technology, today announced that it has signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, the leading pharmaceutical company driving healthcare innovation and access across the Middle East and Africa. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes provisions for Tropis distribution, technology transfer, and manufacturing.

The aim of the collaboration is to increase needle–free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s Tropis® intradermal needle–free delivery offers several strategic advantages for Egypt including substantial polio immunization cost savings1, reduced vaccine hesitancy2,3, increased coverage3, and the potential for medical technology regional manufacturing. The signing follows the July 2025 Memo of Understanding (MOU) that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio.

The introduction of Tropis into immunization programs supports Egypt’s “1000 Golden Days” initiative which was launched to support the health and development of families during the critical period from conception to a child's second birthday. The collaboration will enable total immunization cost reduction and improved acceptability of polio vaccinations. Longer–term, the Tropis manufacturing and other needle–free product development initiatives may expand the benefits to vaccination against other infectious agents and improved pandemic preparedness.

EVA Pharma is a leading pharmaceutical and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, distributing, and promoting pharmaceutical products. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.”

“We are proud to collaborate with ATR and EVA Pharma to localize needle–free manufacturing and delivery,” said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. “This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle–free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.”

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Data on file
2 Soonawala, D et al, Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults, Vaccine, Volume 31, Issue 36, 12 August 2013, Pages 3688–3694
3 Mohan, D et al, Evaluating the impact of needle–free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.533

Media Contacts:
Nancy Lillie
[email protected]
1–888–900–4321 Option 3
Marina Faltas
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a68cea50–6f2b–4c9d–80af–cf4a85632192


GLOBENEWSWIRE (Distribution ID 1001136225)

Inteleos Opens Africa Office to Advance Basic Obstetric Point of Care Ultrasound (OPOCUS) Certification Across East Africa

ROCKVILLE, Md. and NAIROBI, Kenya, Oct. 30, 2025 (GLOBE NEWSWIRE) — Inteleos, a global nonprofit healthcare certification organization, expands its commitment to working on the ground in Africa to elevate the standard of global healthcare with the opening of an office with a dedicated, local team in Nairobi, Kenya. Inteleos Africa, opened in October 2025, will focus on improving the quality of and access to Point–of–Care Ultrasound (POCUS) education and certification in East Africa and beyond.

Improving Outcomes Through Certification

Through education and validation of clinical proficiency by certification, the ultimate goal is to improve maternal and fetal health outcomes. In addition, certification stands to expand economic and employment opportunities for frontline clinicians, especially midwives and nurses. Inteleos will continue its prior work in Kenya in collaboration with the Ministry of Health and their new certification requirements to set standards that other nations will follow as a model for improving maternal–fetal outcomes.

“Certification ensures that the pockets and pilots of POCUS training meet the global standard of proficiency while aligning with the local scope of practice. This ensures sustainable proficiency and accessible quality of care,” noted Pamela Ruiz, Chief Business Development Officer at Inteleos. “Our ongoing collaboration with Kenya’s Ministry of Health and stakeholders on the ground shows how local and global leadership can drive meaningful change.”

Global Experience, Local Impact

Inteleos and its related organizations bring a 50–year legacy of working with communities of practice and institutions to ensure equitable access to quality care through sonography and other imaging certification, including POCUS and obstetric POCUS (OPOCUS) certification programs. Inteleos has certified more than 150,000 healthcare practitioners of varying levels in 113 different countries. As a leading provider of certification in Africa, Inteleos has actively worked in Kenya for the last three years and also brings certifications to the country that are ISO certified.

The first Inteleos Africa executive is Steven Opondo, the new Director of Partnerships and Growth. “Kenya is pioneering approaches that will help transform healthcare outcomes regionally,” said Mr. Opondo. “Having an Inteleos Africa team on the ground will accelerate adoption of international standards and benefit patients across Africa.”

Nairobi was chosen as the location for Inteleos’ first Africa office since Kenya is at the forefront of setting standards and policies that will transform patient care. While OPOCUS certifications are accepted across the globe, Kenya is the only nation that requires certification for OPOCUS trainers. The Kenya Ministry of Health has set out the certification requirements as a part of its National Obstetrics Point of Care Ultrasound (O–POCUS) Guidelines, with the goal of improving maternal and fetal health outcomes.

Supporting Growth and Collaboration

Inteleos Africa will participate in two upcoming events: The Kenya Medical Association OPOCUS training and certification event in late October and the African Venture Philanthropy Alliance (AVPA) conference in early November.

For more information on Inteleos Africa, visit Inteleos.org/Africa_office.

About Inteleos

Inteleos™ is a non–profit organization dedicated to ensuring equitable access to quality healthcare globally. It oversees the American Registry for Diagnostic Medical Sonography® (ARDMS®), the Alliance for Physician Certification & Advancement™ (APCA™), and the Point–of–Care Ultrasound Certification Academy™ (PCA), collectively representing 150,000 certified medical professionals worldwide. The Inteleos Foundation manages the organization’s philanthropic initiatives. Learn more at Inteleos.org.


GLOBENEWSWIRE (Distribution ID 9563521)

Selon la Direction de BONK, Inc. (Nasdaq : BNKK), un rapport de recherche indépendant conclut que la Société est stratégiquement positionnée pour s’imposer comme le principal véhicule coté en bourse de l’écosystème crypto BONK sur la blockchain Solana, à raison d’une valorisation de plusieurs milliards de dollars

Selon le rapport Harbinger, et à l’appui de ses propres estimations indépendantes, la Société devrait enregistrer une forte croissance de son chiffre d’affaires à l’horizon des prochaines années

Harbinger Research entame la couverture de BONK, Inc. avec une recommandation d’achat unique sur le Nasdaq reposant sur un double moteur de revenus et une stratégie déflationniste.

SCOTTSDALE, État d’Arizona, 30 oct. 2025 (GLOBE NEWSWIRE) — Bonk, Inc. (Nasdaq : BNKK), ci–après la « Société », qui détient une réserve de jetons de cryptomonnaie $BONK développée sur la blockchain Solana et destinée à accompagner la démarche d’autonomisation d’un collectif concevant des produits générateurs de revenus, annonce ce jour le début de la couverture de son action par Harbinger Research, qui à la clé d’une analyse approfondie et indépendante fait ressortir la position unique de la Société et son potentiel de croissance majeur depuis sa récente transformation stratégique. Ce rapport détaillé présente Bonk, Inc. comme le « véhicule coté en bourse de référence » pour les investisseurs souhaitant une exposition réglementée à l’écosystème BONK, en plein essor, potentiellement valorisé à plusieurs milliards de dollars et développé sur la blockchain Solana, soit du jamais vu au Nasdaq.

Le rapport rédigé par Harbinger Research (disponible sur https://www.harbingerresearch.com) met en perspective la pertinence de la stratégie de Bonk, Inc. en faisant le point sur la résilience remarquable et la renaissance de la blockchain Solana. En effet, au cours des douze derniers mois, celle–ci a dégagé près de 3 milliards de dollars de chiffre d’affaires. Selon The Motley Fool, elle pourrait devenir le prochain actif numérique pesant 1 000 milliards de dollars. Solana affiche aujourd’hui une croissance supérieure à celle d’Ethereum, notamment dans les domaines clés de la finance décentralisée.i

Longtemps mise en doute après l’effondrement de FTX, Solana s’est, comme le souligne Harbinger, réaffirmée comme un « centre névralgique de l’innovation ». Prisée pour sa rapidité inégalée et ses faibles frais de transaction, Solana se perçoit comme un environnement privilégié pour les actifs numériques orientés vers le grand public. Le rapport revient sur les origines de BONK en rappelant que la Société est née d’un projet collectif visant à redynamiser cet écosystème, devenu par la suite « un actif clé de l’écosystème consommateurs de Solana » En s’intégrant à ce que Harbinger considère comme un réseau florissant, et plus largement au secteur des meme coins, moteur avéré de l’adoption des utilisateurs, Bonk, Inc. propose selon l’analyse indépendante du cabinet une exposition unique à l’un des domaines les plus dynamiques de l’économie des actifs numériques aux investisseurs.

« Nous sommes enchantés que Harbinger Research reconnaisse le modèle à la fois fort et unique que nous développons chez Bonk, Inc. » explique Jarrett Boon, PDG. « Le fait que Harbinger valide notre stratégie confirme ce que nous considérons comme une opportunité majeure pour les investisseurs. Nous bâtissons une passerelle clé inédite entre les marchés boursiers traditionnels et la croissance récurrente d’un écosystème DeFi de premier ordre. Ce modèle à double moteur permet de capter la valeur dégagée à la fois par les flux de trésorerie d’exploitation et par un actif de trésorerie déflationniste. Il entend convertir directement l’expansion dynamique de l’écosystème BONK en valeur tangible pour nos actionnaires et nous placer en tête de cette évolution financière. »

Puis d’ajouter : « Ce rapport démontre que notre Société se trouve non seulement au bon endroit au moment opportun, mais qu’elle a aussi su prendre les bonnes décisions pour capter une part substantielle de ce marché. »

Pour Mitchell Rudy (alias Nom), principal contributeur du projet BONK et membre du Conseil d’administration de Bonk, Inc. : « La recherche menée par Harbinger fait ressortir très justement les atouts clés de BONK, à savoir une communauté colossale et engagée, une réelle utilité venant de ses mécanismes déflationnistes, et une intégration profonde sur Solana. Ce qui rend Bonk, Inc. si exceptionnelle, c’est qu’elle constitue le seul véhicule coté en bourse conçu pour canaliser directement le succès de son écosystème vers les actionnaires. Ce constat n’est pas que théorique. C’est une dynamique économique à part entière et source de valeur. Nous orchestrons un modèle éprouvé, et le rapport de Harbinger valide l’énorme potentiel que nous commençons à peine à laisser entrevoir. »

Confirmant encore l’envergure de sa portée, le rapport Harbinger détaille les estimations indépendantes du cabinet qui s’orientent vers une nette croissance du chiffre d’affaires à l’horizon des prochaines années. L’analyse met en évidence le potentiel du « volant d’inertie économique » intégré au modèle de Bonk, Inc. Il souligne comment la hausse de l’activité au sein de l’écosystème se traduit directement par une augmentation des recettes enregistrées par des plateformes comme letsBONK.fun, pour alimenter ensuite la stratégie de rachat et de destruction de jetons BONK retenue par Bonk, Inc. Selon Harbinger, ce principe se caractérise comme « un cercle vertueux conçu pour donner plus de poids à la rareté et dégager de la valeur à long terme » à l’échelle de tout l’écosystème et, par extension, aux actionnaires de Bonk, Inc.

À propos de Bonk, Inc. Bonk Inc. (Nasdaq : BNKK) est une société dont la mission est d’élever des passerelles entre les marchés boursiers traditionnels et l’univers des actifs numériques. À la suite de son intégration stratégique à letsBONK.fun, la Société déroule une stratégie axée sur l’acquisition d’actifs générateurs de revenus dans l’espace DeFi dans le but de constituer une solide trésorerie en actifs numériques. Sa division boissons englobe les boissons brevetées Sure Shot, conçues pour réduire rapidement l’alcoolémie, et Yerbaé, une boisson énergisante d’origine végétale.

Déclarations prospectives : le présent communiqué de presse contient des déclarations prospectives. Ces déclarations induisent des risques et des incertitudes, dont beaucoup échappent au contrôle de la Société, et qui pourraient faire en sorte que les résultats réels diffèrent sensiblement. Les facteurs pouvant exercer une influence à cet égard comprennent notamment, sans toutefois s’y limiter, la performance des jetons BONK, le succès de l’intégration et de l’opération letsBONK.fun, l’aptitude de la Société à réaliser sa stratégie de trésorerie, et d’autres risques détaillés dans les documents déposés par Safety Shot auprès de la Securities and Exchange Commission.

Relations investisseurs : Tél. : 888–257–8061 Site Internet : BonkDAT.com

SOURCE : Bonk, Inc.

ihttps://www.fool.com/investing/2025/10/27/this–hypergrowth–cryptocurrency–will–be–the–next–1/


GLOBENEWSWIRE (Distribution ID 9565216)

Administração da BONK, Inc. (Nasdaq: BNKK) Declara que Relatório de Pesquisa Independente Concluiu que a Empresa Está Posicionada a Ser Principal Veículo Público do Ecossistema Cripto de Muitos Bilhões de Dólares Via Solana Blockchain

Relatório da Harbinger apresenta um resumo das estimativas independentes da empresa para um crescimento significativo da receita nos próximos anos

Harbinger Research Inicia Cobertura, Destacando Poderoso Mecanismo de Receita Dupla, Estratégia Deflacionária de Ativos e Oportunidade Única na Nasdaq

SCOTTSDALE, Arizona, Oct. 30, 2025 (GLOBE NEWSWIRE) — Bonk, Inc. (Nasdaq: BNKK) (a “Empresa”), que detém uma tesouraria do token de criptomoeda $BONK, criado na blockchain da Solana, com foco na capacitação de uma comunidade de produtos geradores de receita, anunciou hoje o início da cobertura de pesquisa de ações pela Harbinger Research, destacando a análise convincente da empresa independente da posição única e do potencial de crescimento significativo da Empresa após sua recente transformação estratégica. O relatório abrangente identifica a Bonk, Inc. como “principal veículo de mercado público” para investidores que buscam exposição regulamentada do ecossistema BONK, potencialmente de alto crescimento e multibilionário, na blockchain Solana – uma oportunidade única na bolsa Nasdaq.

O relatório da Harbinger Research (disponível em https://www.harbingerresearch.com) contextualiza a importância da estratégia da Bonk, Inc., detalhando a notável resiliência e ressurgimento da blockchain Solana que, nos últimos 12 meses, gerou quase US$3 bilhões em receita e, de acordo com o The Motley Fool, tem o potencial de se tornar o próximo ativo digital de US $1 trilhão. A Solana está crescendo mais rapidamente do que a Ethereum, principalmente nas importantes áreas de finanças descentralizadas.i

Uma vez questionada após o colapso da FTX, a Solana, como Harbinger observa, ressurgiu como um “uma central de inovação”, valorizado por sua velocidade incomparável e baixos custos, tornando–se o ambiente preferido para ativos digitais voltados para o consumidor. O relatório destaca a origem única da BONK como iniciativa impulsionada pela comunidade, lançada especificamente para revitalizar esse ecossistema, evoluindo com sucesso além de um simples meme de um “componente essencial do ecossistema de consumo da Solana”. Ao se posicionar dentro do que acreditamos ser uma rede próspera e de meme de bilhões de dólares do setor de moedas – um mecanismo comprovado para a adoção de usuários – a Bonk, Inc. oferece aos investidores uma exposição única a uma das áreas mais dinâmicas da economia de ativos digitais, validado pela análise independente da Harbinger.

“É um prazer ver a Harbinger Research reconhecer o modelo único e poderoso que estamos criando na Bonk, Inc.”, disse Jarrett Boon, CEO. “A validação da nossa estratégia pela Harbinger confirma o que acreditamos ser uma oportunidade histórica para os investidores. Estamos estabelecendo uma ponte única e essencial para que os mercados públicos possam acessar diretamente a receita recorrente e o crescimento de um ecossistema DeFi líder. Esse modelo ativo e de dois motores – capturando o valor do fluxo de caixa operacional e de um ativo deflacionário da tesouraria – foi projetado para traduzir a expansão vibrante do ecossistema BONK diretamente em um valor tangível para os acionistas, posicionando–nos na vanguarda dessa evolução financeira.”

Ele continuou: “Este relatório confirma que a Empresa, além de estar no lugar certo no momento certo, também tomou as medidas certas para garantir que a Empresa possa captar uma parte substancial desse mercado.”

Mitchell Rudy (ou Nom), um dos principais colaboradores da BONK e membro do conselho da Bonk, Inc., acrescentou: “A pesquisa da Harbinger mostra com precisão os principais pontos fortes da BONK: uma comunidade massiva e engajada, uma mecânica deflacionária real e uma profunda integração com a Solana. O que torna a Bonk, Inc. tão interessante é ser o veículo público exclusivo projetado para canalizar o sucesso desse potente ecossistema diretamente para os acionistas. Isso não é apenas teoria; é a real atividade econômica que gera valor. Estamos executando um modelo comprovado, e o relatório da Harbinger valida o imenso potencial que estamos apenas começando a desbloquear juntos.”

Confirmando ainda mais a escala potencial desse modelo, o relatório Harbinger descreve as estimativas independentes da empresa para um crescimento significativo da receita nos próximos anos. A análise de Harbinger enfatiza o poder do “volante econômico” inerente ao modelo da Bonk, Inc. O relatório detalha como a crescente atividade dentro do ecossistema se traduz diretamente em aumento da receita de plataformas como a letsBONK.fun, que então alimenta o acúmulo estratégico e a queima de tokens BONK por meio da estratégia de reinvestimento da Bonk, Inc. Isso cria o que Harbinger descreve como um “ciclo virtuoso projetado para aumentar a escassez e gerar valor a longo prazo” para todo o ecossistema e, por extensão, para os acionistas da Bonk, Inc.

Sobre a Bonk, Inc. A Bonk, Inc. (Nasdaq: BNKK), é uma empresa em evolução que preenche a lacuna entre os mercados públicos tradicionais e o ecossistema de ativos digitais. Após sua integração estratégica com a letsBONK.fun, a Empresa passou a executar uma nova estratégia focada na aquisição de ativos geradores de receita dentro do espaço DeFi para a criação de uma tesouraria robusta de ativos digitais. A divisão de bebidas da Empresa conta com a bebida patenteada Sure Shot, criada para reduzir rapidamente o teor de álcool no sangue, bem como a bebida energética à base de plantas Yerbaé.

Declaração de Previsão: Este comunicado para a imprensa contém declaração de previsão. Tais declarações estão sujeitas a riscos e incertezas, muitos dos quais fora do controle da Empresa, e os resultados reais podem ser substancialmente diferentes. Os fatores que podem causar ou contribuir para tais diferenças incluem, mas não estão limitados a, o desempenho dos tokens BONK, a integração bem–sucedida com a letsBONK.fun e o seu sucesso operacional, a capacidade de executar a estratégia de tesouraria da Empresa e outros riscos detalhados nos registros da Safety Shot na Comissão de Valores Mobiliários.

Relações com Investidores Telefone: 888–257–8061 Website: BonkDAT.com

FONTE: Bonk, Inc.

ihttps://www.fool.com/investing/2025/10/27/this–hypergrowth–cryptocurrency–will–be–the–next–1/


GLOBENEWSWIRE (Distribution ID 9565216)

BONK, Inc. (Nasdaq:BNKK) Management Says Independent Research Report Concludes Company Is Positioned To Be The Premier Public Vehicle For Multi-Billion Dollar BONK Crypto Ecosystem Via Solana Blockchain

The Harbinger Report Outlines The Firm's Independent Estimates For Significant Revenue Growth In The Coming Years

Harbinger Research Initiates Coverage, Highlighting Powerful Dual Revenue Engine, Deflationary Asset Strategy, And Unique Opportunity On Nasdaq

SCOTTSDALE, Ariz., Oct. 29, 2025 (GLOBE NEWSWIRE) — Bonk, Inc. (Nasdaq: BNKK) (the “Company”), which holds a treasury of the $BONK cryptocurrency token built on the Solana blockchain, focused on empowering a community building revenue generating products, today announced the initiation of equity research coverage by Harbinger Research, highlighting the independent firm’s compelling analysis of the Company's unique position and significant growth potential following its recent strategic transformation. The comprehensive report frames Bonk, Inc. as the “premier public–market vehicle” for investors seeking regulated exposure to the potentially high–growth, multi–billion dollar BONK ecosystem on the Solana blockchain – a unique opportunity on the Nasdaq exchange.

Harbinger Research's report (available at https://www.harbingerresearch.com) contextualizes the significance of Bonk, Inc.'s strategy by detailing the remarkable resilience and resurgence of the Solana blockchain which over the past 12 months, generated nearly $3 billion in revenue and according to The Motley Fool, has the potential to become the next $1 trillion digital asset. Solana is now growing faster than Ethereum, especially in key areas such as decentralized finance.i

Once questioned following the FTX collapse, Solana, as Harbinger notes, has re–emerged as a “central hub for innovation,” prized for its unmatched speed and low costs, making it the preferred environment for consumer–facing digital assets. The report highlights BONK's unique origin as a community–driven initiative launched specifically to revitalize this ecosystem, successfully evolving beyond a simple meme into an “essential component of Solana's consumer ecosystem.” By positioning itself within this what we believe to be a thriving network and the broader, multi–billion dollar meme coin sector—a proven engine for user adoption—Bonk, Inc. offers investors unique exposure to one of the most dynamic areas of the digital asset economy, as validated by Harbinger's independent analysis.

“We are pleased to see Harbinger Research recognize the unique and powerful model we are building at Bonk, Inc.,” said Jarrett Boon, CEO. “Harbinger’s validation of our strategy confirms what we believe is a landmark opportunity for investors. We’re building a unique and essential bridge for the public markets to directly access the recurring revenue and growth of a leading DeFi ecosystem. This active, dual–engine model—capturing value from both operational cash flow and a deflationary treasury asset—is designed to translate the BONK ecosystem’s vibrant expansion directly into tangible shareholder value, positioning us at the forefront of this financial evolution.”

He continued: “This report verifies that the Company is not only in the right place at the right time but they’ve also taken the right steps to ensure the Company can capture a substantial portion of this market.”

Mitchell Rudy (a.k.a. Nom), a BONK core contributor and board member of Bonk, Inc., added, “Harbinger’s research accurately captures BONK’s core strengths: a massive, engaged community, real utility driving deflationary mechanics, and deep Solana integration. What makes Bonk, Inc. so compelling is that it’s the exclusive public vehicle designed to channel this powerful ecosystem's success directly to shareholders. This isn't just theory; it’s real economic activity driving value. We are executing a proven model, and Harbinger's report validates the immense potential we are just beginning to unlock together.”

Further validating the potential scale of this model, the Harbinger report outlines the firm's independent estimates for significant revenue growth in the coming years. Harbinger's analysis emphasizes the power of the “economic flywheel” inherent in Bonk, Inc.'s model. The report details how growing activity within the ecosystem directly translates into increased revenue for platforms like letsBONK.fun, which then fuels the strategic accumulation and burning of BONK tokens via Bonk, Inc.'s reinvestment strategy. This creates what Harbinger describes as a “virtuous cycle designed to enhance scarcity and drive long–term value” for the entire ecosystem and, by extension, Bonk, Inc. shareholders.

About Bonk, Inc. Bonk, Inc. (Nasdaq: BNKK), is a company evolving bridge the gap between traditional public markets and the digital asset ecosystem. Following its strategic integration with letsBONK.fun, the Company is executing a new strategy focused on acquiring revenue–generating assets within the DeFi space to build a robust treasury of digital assets. The Company’s beverage division holds the patented Sure Shot beverage, designed to rapidly reduce blood alcohol content as well as Yerbaé’s plant–based, energy beverage.

Forward–Looking Statements: This press release contains forward–looking statements. Such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, and actual results could differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the performance of BONK tokens, the successful integration and operational success with letsBONK.fun, the ability to execute on the Company’s treasury strategy, and other risks detailed in Safety Shot’s filings with the Securities and Exchange Commission.

Investor Relations: Phone: 888–257–8061 Website: BonkDAT.com

SOURCE: Bonk, Inc.

i https://www.fool.com/investing/2025/10/27/this–hypergrowth–cryptocurrency–will–be–the–next–1/


GLOBENEWSWIRE (Distribution ID 9564217)

Transforming Global Healthcare: Inteleos Debuts Sonography Certification at Eight New UAE Testing Centers

New Locations Unlock Regional Access to Certification, Expand Opportunity for Professionals to Obtain ISO–Certified Credentials

Healthcare credentialing leader advances equity and excellence in diagnostic ultrasound for clinicians throughout the UAE

ROCKVILLE, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) — Inteleos, global certifying body for over 150,000 medical professionals worldwide, announced eight new testing sites across the United Arab Emirates. Through this unprecedented access, Inteleos will offer clinicians direct, in–region examinations for their portfolio of ISO–17024 accredited certifications.  

Leading with the gold–standard Registered in Musculoskeletal® Sonography Certification (RMSK®) certification, the new sites will support clear, simple accreditation across specialties—empowering healthcare providers with advanced ultrasound credentials and ushering in a new era of support for expert care across the region.  

The newly established locations represent Inteleos’ commitment to healthcare excellence at a global scale, targeting equity in education, professional validation, and patient care outcomes.   

“This expansion reflects Inteleos’ mission: that high–quality healthcare and professional certification should be accessible to all providers, wherever they practice,” said Pamela Ruiz, Chief Business Development Officer, Inteleos. “Our new UAE testing locations make it possible for more clinicians to earn industry–leading MSK credentials, benefit from joining an international community of practice, and deliver the best care to their patients anywhere in the world.” 

By leading with the flagship RMSK credential, Inteleos invites physiotherapists, physicians, and other medical professionals to demonstrate their expertise in musculoskeletal ultrasound imaging. This critical diagnostic tool supports both individual clinicians and full–service practices, including specialists in orthopedics, sports medicine, and rheumatology.  

The RMSK credential is expertly designed to validate both the depth and breadth of providers’ ability in diagnostic ultrasound—including knowledge in bone, muscle, tendon, and nerve imaging, as well as guided interventional procedures. The 2025 application period is open now and will close on October 7. Exam administration runs from October 20 through November 21. Point–of–care ultrasound (POCUS) certification exams for MSK are available year–round. 

Clinicians earning the RMSK certification join a vibrant global community, opening doors to further specializations and career opportunities. To learn more or register for the next testing window at a UAE location, visit www.inteleos.org/uae/. 

About Inteleos  

Inteleos™ is a non–profit organization dedicated to ensuring equitable access to quality healthcare globally. It oversees the American Registry for Diagnostic Medical Sonography® (ARDMS®), the Alliance for Physician Certification & Advancement™ (APCA™), and the Point–of–Care Ultrasound Certification Academy™ (PCA), collectively representing 150,000+ certified medical professionals worldwide. The Inteleos Foundation manages the organization’s philanthropic initiatives. 


GLOBENEWSWIRE (Distribution ID 9529436)

e Sono and POCUS Certification Academy Launch Ultrasound Proficiency On-Demand Bundles for Key Clinical and Specialty Certifications

HAMBURG, Germany and ROCKVILLE, Md., June 10, 2025 (GLOBE NEWSWIRE) — e Sono (by 3B Scientific), a globally recognized leader in clinical ultrasound simulation, and the POCUS Certification Academy, a globally trusted provider of point–of–care ultrasound (POCUS) education and certification and part of the Inteleos non–profit organization, have partnered to offer new bundled packages to advance ultrasound proficiency. The bundles combine e Sono’s interactive, real case–based online ultrasound simulation courses with the POCUS Certification Academy’s Clinical and Specialty Certifications – providing a comprehensive path to hands–on learning and professional credentialing.

The on–demand bundles provide clinicians with comprehensive, evidence–based training and a clear pathway to validate their ultrasound proficiency in key clinical areas, including Abdominal, Musculoskeletal (MSK), and OB/GYN Maternal Fetal Health.

As point–of–care ultrasound (POCUS) becomes an essential tool across medical specialties, the demand for accessible, high–quality education, training, and rigorous certification continues to grow. These new bundles address this need by integrating e Sono’s hands–on ultrasound simulation–recently recognized as an Approved POCUS Education Provider™–with the POCUS Certification Academy’s globally respected certification process. Clinicians benefit from real–patient case simulations, immediate feedback, and a streamlined path to earning credentials that are trusted worldwide, ultimately improving diagnostic accuracy and patient care.

“By combining e Sono’s high–fidelity ultrasound simulation training with the POCUS Certification Academy’s rigorous certification process, we are empowering clinicians everywhere to build and validate their ultrasound skills with confidence anytime, anywhere” said Adi Baruch, Executive at e Sono”. This partnership sets a new standard for innovative, accessible, and high–impact ultrasound education and training.”

“POCUS is rapidly becoming the new stethoscope, with a growing number of users entering the field,” explained Jasmine Rockett, Director of POCUS Certification Academy. “Ultrasound learning requires extensive clinical training alongside theoretical instruction. e Sono’s unique technology allows users to train with real ultrasound scenarios anytime, anywhere, from any internet–connected device,” Rockett continued. “This enables them to combine theoretical knowledge provided by POCUS.org with hands–on practice, ultimately enhancing their ultrasound skills.”

The e Sono and POCUS Certification Academy Bundles are available now online, allowing clinicians around the world to learn at their own pace and on their own schedule.

About e Sono and 3B Scientific

e Sono (by 3B scientific) is a cutting–edge, web–based SaaS ultrasound simulator designed to meet the evolving needs of modern ultrasound education. e Sono is committed to revolutionizing clinical ultrasound training and making it accessible to all, e Sono partners with the world’s leading POCUS organizations to deliver a top–quality, real–life ultrasound training experience. It empowers learners and clinicians at all levels to practice and simulate realistic ultrasound scenarios anytime, anywhere — without the need for specialized equipment.

About 3B Scientific

3B Scientific, established in 1948 in Hamburg, Germany, is a global provider of state–of–the–art medical simulators and educational products for healthcare and veterinary training. With a presence in over 120 countries, the 3B Scientific Group continues to drive its mission of advancing the delivery of medical and veterinary education worldwide.

About Point–of–Care–Ultrasound Academy

Point–of–Care Ultrasound (POCUS) Certification Academy offers globally recognized certifications for healthcare providers to independently validate their POCUS knowledge, application, and proficiency. POCUS partners with constituents through rigorous assessments, continual learning opportunities, and community building around important topics relevant to POCUS.

About Inteleos

Inteleos™ is a non–profit organization dedicated to ensuring equitable access to quality healthcare globally. It oversees the American Registry for Diagnostic Medical Sonography® (ARDMS®), the Alliance for Physician Certification & Advancement™ (APCA™), and the Point–of–Care Ultrasound Certification Academy™ (PCA), collectively representing 150,000+ certified medical professionals worldwide. The Inteleos Foundation manages the organization’s philanthropic initiatives.


GLOBENEWSWIRE (Distribution ID 9465822)

Emirati Women Chapter Onboards Second Cohort of 62 Participants

ABU DHABI, United Arab Emirates, April 09, 2025 (GLOBE NEWSWIRE) — Under the patronage of Her Highness Sheikha Fatima bint Mubarak, Chairwoman of the General Women's Union (GWU), President of the Supreme Council for Motherhood and Childhood (SCMC), Supreme Chairwoman of the Family Development Foundation (FDF), and Mother of the Nation,  and in partnership with the General Women’s Union, PureHealth, the largest healthcare group in the Middle East, announced the onboarding of the Emirati Women Chapter’s (EWC) second cohort for 2025, welcoming 62 participants.

The onboarding follows the announcement of the expansion of the EWC programme, introducing a new track specifically tailored for senior Emirati women, while also ensuring the integration of People of Determination within the programme. The second cohort has attracted more than double the participants compared to last year, reflecting the growing demand for the EWC’s transformative programme. This year, the programme expands its impact by fostering a more inclusive and dynamic environment, with a particular focus on senior Emirati women and People of Determination. Over nine months, participants will engage in a comprehensive experience that combines personal coaching, mentorship, and immersive learning opportunities, equipping them with the skills and insights to drive meaningful change in their communities and beyond.

Her Excellency Noura Al Suwaidi, Secretary General of GWU, said, “The continued success of the Emirati Women Chapter is a powerful testament to the strength of collaboration and the shared commitment to advancing women’s roles in society. I am proud to witness the increasing involvement of senior Emirati women, whose wisdom and experience are invaluable in shaping the future of our society. Together, we are paving the way for a more inclusive and prosperous future for all Emirati women.”

Her Excellency Al Rym Abdullah Al Falasi, Secretary–General of SCMC, said, “The EWC programme brings together Emirati women who are eager to grow, connect, and contribute. It’s inspiring to see senior participants join this journey, sharing their experiences and making a meaningful impact on future generations.”

Shaista Asif, Group Chief Executive Officer of PureHealth, said, “The Emirati Women Chapter continues to be a powerful force for growth and empowerment, and welcoming this exceptional group of women to the second cohort is truly inspiring. Their dedication, experiences, and drive to create change will not only shape their own journeys but also inspire future generations, leaving a lasting impact on community. We are honoured to have the patronage of Her Highness Sheikha Fatima bint Mubarak, whose unwavering commitment to empowering Emirati women continues to inspire this programme. We also extend our gratitude to the General Women’s Union and the Supreme Council for Motherhood and Childhood for their invaluable support in nurturing this initiative.”

Sheikha Moza bint Khalifa bin Mohammed Al Nahyan has been appointed as the Ambassador of the Senior Emirati Women Programme, a key initiative that strengthens the EWC programme and contributes to the Year of Community. She will play a key role in preserving and passing on the rich traditions of Emirati culture, ensuring they continue to inspire future generations. Her involvement highlights the programme’s tangible impact, supporting elder–focused initiatives in collaboration with key stakeholders. At the onboarding event, Sheikha Moza reinforced her commitment to empowering senior Emirati women and ensuring their contributions remain integral to society.

With the onboarding of its second cohort, the Emirati Women Chapter continues to grow as a platform for leadership, inclusivity, and social impact. This year’s expanded programme not only strengthens the role of senior Emirati women but also integrates People of Determination, reinforcing a vision of a more connected and empowered society. As participants embark on this transformative journey, they are poised to lead initiatives that will contribute to the Year of Community 2025, shaping a future driven by collaboration, resilience, and meaningful change.

About PureHealth: 

PureHealth is the largest healthcare group in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 100+ hospitals, 300+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare as the company is on a mission to unlock time for humankind. By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. 

PureHealth’s network comprises:  

  • SEHA – One of the largest healthcare networks of hospitals and clinics in the UAE 
  • SEHA CLINICS – Delivering comprehensive community–based healthcare services 
  • Daman (The National Health Insurance Company) – The UAE’s leading health insurer 
  • The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. The President of the UAE 
  • Rafed – The UAE’s largest healthcare Group Purchasing Organisation 
  • PureLab – Managing and operating the largest network of laboratories in the region   
  • One Health – A network that provides end–to–end medical solutions to a base of over 300 healthcare service providers 
  • The Life Corner – Abu Dhabi’s first holistic pharmacy, serving the health and wellness establishment 
  • Ardent Health Services – The fourth largest privately held acute care hospital operator in the US 
  • Circle Health Group – The largest independent operators of hospitals in the UK  
  • Hellenic Healthcare Group (HHG) – the largest private healthcare provider in Greece and Cyprus 
  • PureCS – A leading cloud and technology services provider, specialising in IT management and consulting solutions, cybersecurity, cloud services and AI information systems 
  • Sheikh Shakhbout Medical City (SSMC) – The UAE’s largest healthcare complex, delivering integrated complex care 

To learn more, please visit www.purehealth.ae 

Contact:
Louise Marcel Crouch
[email protected]
+97144473338


GLOBENEWSWIRE (Distribution ID 9419426)